Media & Investors

Press Releases

TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development

Basel, Switzerland, 07/06/2022

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients with their first-in-class Ta:RNA™ platform, today announced two major milestones - the appointment of Dr Marc Thommen as Head of Technical Development, and the successful completion of GLP/Tox studies....

Read more

TargImmune Announces Another Senior Hire as Veronica Hersberger Revealed As New Chief Medical Officer

Basel, Switzerland, 07/02/2022

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients by developing novel targeted anticancer treatments, today announced the further expansion of their management team with the appointment of Veronica Hersberger as Chief Medical Officer (CMO)....

Read more

Christoph Rentsch Announced as Chief Financial Officer for TargImmune

Basel, Switzerland, 01/10/2021

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients by developing novel targeted anticancer treatments, today announced the appointment of Christoph Rentsch as full-time Chief Financial Officer (CFO)....

Read more

TargImmune successfully closed its 2021 financing round and appoints Peter Braun as Chief Executive Officer

Basel, Switzerland, 09/07/2021

TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on the development of new medicines through the use of novel targeted immunotherapies, today announced that Peter Braun, who has extensive experience in the healthcare industry and most recently led the biopharmaceutical company Nordic Nanovector, has been appointed Chief Executive Officer (CEO), effective August 16, 2021. He will succeed Esteban Pombo-Villar, who has built the company over the past four years and will now focus on leading key projects in chemistry and biology as Chief Technology Officer (CTO)....

Read more

TargImmune in the Media

TargImmune in Nature Biopharma Dealmakers

Basel, Switzerland, 07/06/2022

Learn more about how TargImmune are TAIMing cancer by harnessing the body’s antiviral defences in Nature Biopharma Dealmakers ...

Read more

Journalists

The TargImmune team are always happy to speak with journalists.

If you are a journalist who would like to speak with us, please contact media@targimmune.com

Specimin slide on microscope

Potential Investors

TargImmune are open to discussions with potential investors.

If you would like to speak with us about investment opportunities, please contact IR@targimmune.com

Scientific container